Eloralintide
Also known as: PC-DAP, Long-acting amylin analog, OPKO amylin
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
~7 days (estimated, long-acting design)
Route
SubQ
Category
GLP-1 / Weight Loss Agonists
Studies
4 references
Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
Mechanism of Action
Eloralintide binds calcitonin receptor and RAMP complexes (amylin receptors) in the central nervous system, particularly the area postrema and hypothalamus. Activation of these receptors suppresses appetite, slows gastric emptying, reduces post-prandial glucagon, and promotes satiety signals. Its extended half-life via structural modifications enables once-weekly administration, overcoming the major limitation of pramlintide which requires multiple daily injections.
Dosing Protocols
Investigational Protocol (Research Reference)
- Dose
- Under investigation in Phase 1/2 trials
- Frequency
- Once weekly
- Timing
- Subcutaneous injection
- Cycle
- Per clinical trial protocol
Exact dosing ranges from clinical trials not yet publicly established. For research awareness only — not approved for clinical use.
Calculate your draw volume
Enter your vial size and BAC water to get exact injection volumes
Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- Hypoglycemia (when combined with insulin)
Contraindications
Not FDA approved — investigational compound. Hypersensitivity to amylin analogs. Use caution with insulin-based therapies due to hypoglycemia risk.
Storage
Per manufacturer guidelines. Likely refrigeration at 2–8°C standard for peptide compounds.
Clinical Research
- 1.Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey CJ, Flatt PR, Conlon JM · Peptides · 2026ReviewPubMed Verified
- 2.Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA et al. · Diabetes, obesity & metabolism · 2026PubMed Verified
- 3.Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS et al. · Lancet (London, England) · 2025RCTPubMed Verified
- 4.Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T et al. · Molecular metabolism · 2025RCTPubMed Verified
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.
Was this page helpful?
Launching soon
Build and track your protocol in Staqk
Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.